Research Industries/Vascular Technologies
This article was originally published in The Gray Sheet
Executive Summary
Enter exclusive, worldwide marketing agreement under which Research Industries will distribute two Vascular Technologies probes that are "targeted for introduction in early fiscal 1994" (year beginning July 1). One probe "provides real-time pH and temperature in a patient's heart during bypass surgery," while the other, "by means of ultrasound, locates a patient's mammary artery to be salvaged for bypass graft material and also confirms that a new artery graft is open and functioning prior to concluding the surgery," Research Industries says.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.